Nixon Ronald T 4
4 · Sanara MedTech Inc. · Filed Jun 5, 2026
Research Summary
AI-generated summary of this filing
Sanara MedTech (SMTI) 10% Owner Ronald T. Nixon Receives 4,154-Share Award
What Happened
Ronald T. Nixon, a 10% owner of Sanara MedTech, was granted 4,154 shares of restricted common stock on 2026-06-04. The shares were issued at $0.00 (award/grant) and therefore show no cash purchase value at grant. The restricted stock vests on the earlier of the company's 2027 annual meeting or June 4, 2027, provided Mr. Nixon continues to provide certain services through that date.
Key Details
- Transaction date: 2026-06-04; Filing date: 2026-06-05 (timely filing).
- Transaction type/code: Award/Grant (A); 4,154 shares granted at $0.00 each (total $0 at grant).
- Vesting: Earlier of the 2027 annual shareholder meeting or June 4, 2027, subject to continued service.
- Shares owned after transaction: Not specified in the provided extract.
- Footnotes of note:
- F1: Grant made under the 2024 Omnibus Long-Term Incentive Plan with the vesting terms above.
- F2–F3: Mr. Nixon may be deemed to share voting/dispositive control over additional shares held of record by affiliated entities (CGI Cellerate RX, LLC; FA Sanara, LLC) due to his roles in related entities; those entities and Mr. Nixon disclaim beneficial ownership except to the extent of pecuniary interest.
Context
This was a compensation-related restricted stock grant, not an open-market purchase or sale. Such awards are typical for executive/owner compensation and do not directly signal a market buy or sell. As a reported 10% owner and manager of affiliated entities, Mr. Nixon is connected to additional record holdings through subsidiaries (per footnotes), which affects disclosure of shared control but does not necessarily change beneficial ownership assertions.
Insider Transaction Report
- Award
Common Stock
[F1]2026-06-04+4,154→ 68,196 total
- 2,452,731(indirect: See Footnote)
Common Stock
[F2] - 963,856(indirect: See Footnote)
Common Stock
[F3]
Footnotes (3)
- [F1]Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Issuer") to the reporting person pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The restricted stock will vest on the earlier of (i) the date of the 2027 annual shareholder meeting or (ii) June 04, 2027, provided that the reporting person is providing certain services to the Issuer through such date.
- [F2]Represents shares of the Issuer's common stock owned of record by CGI Cellerate RX, LLC, which is a wholly owned subsidiary of Catalyst Rochal, LLC. Mr. Nixon is a manager of Catalyst Rochal, LLC. By virtue of these relationships, Mr. Nixon, Catalyst Rochal, LLC and CGI Cellerate RX, LLC may be deemed to share voting and dispositive control over the common stock. Mr. Nixon and Catalyst Rochal, LLC disclaim beneficial ownership of any common stock held or beneficially owned by CGI Cellerate RX, LLC, except to the extent of each of their pecuniary interests therein.
- [F3]Represents shares of the Issuer's common stock owned of record by FA Sanara, LLC ("FA Sanara"). FA Sanara is managed by Family Alignment, LLC ("Family"), which is managed by Catalyst Group, Inc. ("Catalyst"). Mr. Nixon is a controlling shareholder and President of Catalyst. Mr. Nixon, Catalyst, Family and FA Sanara may be deemed to share voting and dispositive control over the common stock. Mr. Nixon, Catalyst and Family disclaim beneficial ownership of any common stock held or beneficially owned by FA Sanara, except to the extent of each of their pecuniary interests therein.